To explore whether the CD40L–CD40 pathway, as well as associated pathways, were upregulated in patients with CHD suffering from comorbidities, we performed plasma proteomic analysis of CHD patients with either hypertension (HT) or hypertension and diabetes (HT + T2DM) using the Olink IMMUNO-ONCOLOGY panel. This evidence concerns the gene CD40 and diabetes mellitus.